Research study for adults with Primary Sclerosing Cholangitis


16620

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)

Medicine

Caldwell Stephen, H

UVa Health System Division of Gastroenterology seeks adults ages 18-65 with Primary Sclerosing Cholangitis (PSC) for a research study. The purpose of the study is determine if a new drug, simtuzumab, is effective effective at preventing the progression of liver fibrosis (scarring) in people with Primary Sclerosing Cholangitis (PSC – an inflammatory disease of the liver bile ducts) ? All study-related procedures and medication provided free of charge. ? Compensation for study visits provided Contact Information: For more information please contact: • Jennifer A. Greene, RN • 434-982-0709 or jag7fh@virginia.edu • Insert IRB-HSR # 16620 Principal Investigator: Stephen Caldwell, MD

Gastroenterology & Hepatology (Digestive Health)

Adult

Primary Sclerosing Cholangitis (PSC)
Liver Disease

Gastroenterology/Hepatology

Ill

Compensation for study visits provided

Jennifer Greene

jag7fh@virginia.edu

4349820709